Improved long-term outcome with long-acting risperidone treatment of chronic schizophrenia with prior partial response

Journal of Psychiatric Practice

Volumn 12, Issue 1, 2006, Pages 55-57

  Lindenmayer, Jean Pierre ^d   Parak, Mohan ^d   Gorman, Jack M ^a,b,c  

^a MCLEAN HOSPITAL   (United States)

^b Partners Psychiatry and Mental Health   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; GABAPENTIN; OLANZAPINE; PLACEBO; RISPERIDONE; VALPROIC ACID; NEUROLEPTIC AGENT;

ADULT; ARTICLE; CASE REPORT; CHRONIC DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EMPLOYMENT; HUMAN; LIVER TOXICITY; LONG TERM CARE; MALE; MENTAL DISEASE; PARANOID SCHIZOPHRENIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PSYCHOPHARMACOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; DELAYED RELEASE FORMULATION; MIDDLE AGED;

ANTIPSYCHOTIC AGENTS; CHRONIC DISEASE; DELAYED-ACTION PREPARATIONS; HUMANS; MALE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA, PARANOID; TREATMENT OUTCOME;

EID: 33646186833     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200601000-00009     Document Type: Article

References (8)

1. Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002;159:255-62.
2. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57(Suppl 11):53-60.
3. Kane J. Progress defined - short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol 2001;16(Suppl 1):S1-8.
4. Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16-22.
5. Kane JM., Eerdekens M, Turner M, et al. Long-acting injectable risperidone: Efficacy and safety of the first long-acting atypical antipsychotics. Am J Psych 2003;160:1125-32.
6. Chue P, Devos E, Duchesne I, et al. One-year hospitalization rates in patients during long-term treatment with long-acting risperidone injection. Value Health 2003;5:229.
7. Turner M, Eerdekens E, Jacko M, et al. Long-acting injectable risperidone: Safety and efficacy in stable patients switched from conventional depot antipsychotics. Int Clin Psychopharmacol. 2004;19:241-9.
8. Lasser RA, Bossie CA, Gharabawi GM, et al. Patients with schizophrenia previously stabilized on conventional depot antipsychotics experience significant clinical improvements following treatment with long-acting risperidone. Eur Psychiatry 2004;19:219-25.